Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT02023060
Recruiting Observational

Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation

NCT02023060 · tracked via the Priya Life Science Israel tracker
Sponsor
Sheba Medical Center
Phase
Observational
Started
2013-11
Last updated
2023-11-29

Condition(s) studied

Trans Catheter Aortic ValveAortic Stenosis

Study summary

The objective is to observe trends in patient characteristics and outcomes after aortic or mitral transcatheter heart valve replacement over time.

Eligibility

Sex
ALL
Min age
18 Years
Max age
110 Years
Healthy volunteers
No
Inclusion Criteria: 1. Subject selected for transcatheter heart valve replacement 2. Signed informed consent to participate in the study Exclusion Criteria: 1. Inability to sign written informed consent. 2. Pregnancy or breast feeding (women of childbearing potential will have a serum or urine pregnancy test).

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Hadassah Medical Center Jerusalem Israel Recruiting
Shaarei Zedek amedical Center Jerusalem Israel Recruiting
Rabin Medical Center Petah Tikva Israel Recruiting
Sheba Medical Center Ramat Gan Israel Recruiting
Tel Aviv Medical Center Tel Aviv Israel Recruiting

More Sheba Medical Center trials in Israel

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer Recruiting
Clemastine Treatment in Individuals With Williams Syndrome Active, not recruiting
Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury Recruiting
Hepatopulmonary Radio-sterilization With Immunotherapy Starting soon
ALK Digital Pathology Outcome Predition, Multi Institutional, Restrospective Study Enrolling by invitation

Other trials for the same condition

PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis Active, not recruiting
Post-Market Clinical Follow Up Study With Navitor Valve Recruiting
PARTNER 3 Trial - Aortic Valve-in-Valve Recruiting
A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02023060 on ClinicalTrials.gov ↗ ← All trials in Israel